A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
Follicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells mediating antibody-dependent cell cycotoxicity (...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01943/full |
id |
doaj-edac4580725a42f69c8ffc364c78d22b |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Emilie Decaup Emilie Decaup Emilie Decaup Cédric Rossi Cédric Rossi Cédric Rossi Cédric Rossi Pauline Gravelle Pauline Gravelle Pauline Gravelle Pauline Gravelle Camille Laurent Camille Laurent Camille Laurent Camille Laurent Julie Bordenave Julie Bordenave Julie Bordenave Marie Tosolini Anne Tourette Emeline Perrial Charles Dumontet Mary Poupot Mary Poupot Mary Poupot Christian Klein Ariel Savina Jean-Jacques Fournié Jean-Jacques Fournié Jean-Jacques Fournié Christine Bezombes Christine Bezombes Christine Bezombes |
spellingShingle |
Emilie Decaup Emilie Decaup Emilie Decaup Cédric Rossi Cédric Rossi Cédric Rossi Cédric Rossi Pauline Gravelle Pauline Gravelle Pauline Gravelle Pauline Gravelle Camille Laurent Camille Laurent Camille Laurent Camille Laurent Julie Bordenave Julie Bordenave Julie Bordenave Marie Tosolini Anne Tourette Emeline Perrial Charles Dumontet Mary Poupot Mary Poupot Mary Poupot Christian Klein Ariel Savina Jean-Jacques Fournié Jean-Jacques Fournié Jean-Jacques Fournié Christine Bezombes Christine Bezombes Christine Bezombes A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma Frontiers in Immunology ADCC—antibody dependent cellular cytotoxicity NK cells modelization 3D co-culture model follicular lymphoma |
author_facet |
Emilie Decaup Emilie Decaup Emilie Decaup Cédric Rossi Cédric Rossi Cédric Rossi Cédric Rossi Pauline Gravelle Pauline Gravelle Pauline Gravelle Pauline Gravelle Camille Laurent Camille Laurent Camille Laurent Camille Laurent Julie Bordenave Julie Bordenave Julie Bordenave Marie Tosolini Anne Tourette Emeline Perrial Charles Dumontet Mary Poupot Mary Poupot Mary Poupot Christian Klein Ariel Savina Jean-Jacques Fournié Jean-Jacques Fournié Jean-Jacques Fournié Christine Bezombes Christine Bezombes Christine Bezombes |
author_sort |
Emilie Decaup |
title |
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma |
title_short |
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma |
title_full |
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma |
title_fullStr |
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma |
title_full_unstemmed |
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma |
title_sort |
tridimensional model for nk cell-mediated adcc of follicular lymphoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2019-08-01 |
description |
Follicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells mediating antibody-dependent cell cycotoxicity (ADCC) in the peripheral blood of FL patients predict the outcome. However, their presence in FL biopsies, their activation and their role have been poorly investigated. Moreover, in vitro studies have not deciphered the exact signaling cascades triggered by NK cells in presence of anti-CD20 mAbs on both effector and target cells in a relevant FL model. We performed in silico analyses and ex vivo functional assays to determine the presence and the activation status of NK cells in FL biopsies. We modelized ADCC phenomenon by developing a co-culture model composed by 3D-cultured FL cells and NK cells. Thus, we investigated the biological effect of anti-CD20 mAbs by fluorescent microscopy and the phosphorylation status of survival pathways by cell bar coding phosphoflow in target cells. In parallel, we measured the status of activation of downstream FcγRIIIa signaling pathways in effector cells and their activation (CD69, perforin, granzyme B, IFNγ) by flow cytometry. We determined by in vivo experiments the effects of anti-CD20 mAbs in presence of NK cells in SCID-Beige engrafted FL mice. Here, we show that functional NK cells infiltrate FL biopsies, and that their presence tends to correlate with the survival of FL patients. Using our 3D co-culture model, we show that rituximab and GA101 are able to promote degranulation, CD69 expression, IFNγ production and activate FcγRIIIa signaling cascade in NK cells, and inhibit survival pathways and induce apoptosis in FL cells. The effect of GA101 seems to be more pronounced as observed in vivo in a xenograft FL model. This study strongly supports the role of NK cells in FL and highlights the application of the 3D co-culture model for in vitro validation. |
topic |
ADCC—antibody dependent cellular cytotoxicity NK cells modelization 3D co-culture model follicular lymphoma |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.01943/full |
work_keys_str_mv |
AT emiliedecaup atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT emiliedecaup atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT emiliedecaup atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT juliebordenave atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT juliebordenave atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT juliebordenave atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marietosolini atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT annetourette atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT emelineperrial atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT charlesdumontet atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marypoupot atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marypoupot atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marypoupot atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christianklein atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT arielsavina atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT jeanjacquesfournie atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT jeanjacquesfournie atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT jeanjacquesfournie atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christinebezombes atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christinebezombes atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christinebezombes atridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT emiliedecaup tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT emiliedecaup tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT emiliedecaup tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT cedricrossi tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT paulinegravelle tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT camillelaurent tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT juliebordenave tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT juliebordenave tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT juliebordenave tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marietosolini tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT annetourette tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT emelineperrial tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT charlesdumontet tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marypoupot tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marypoupot tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT marypoupot tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christianklein tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT arielsavina tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT jeanjacquesfournie tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT jeanjacquesfournie tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT jeanjacquesfournie tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christinebezombes tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christinebezombes tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma AT christinebezombes tridimensionalmodelfornkcellmediatedadccoffollicularlymphoma |
_version_ |
1716750379170922496 |
spelling |
doaj-edac4580725a42f69c8ffc364c78d22b2020-11-24T21:12:38ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-08-011010.3389/fimmu.2019.01943461510A Tridimensional Model for NK Cell-Mediated ADCC of Follicular LymphomaEmilie Decaup0Emilie Decaup1Emilie Decaup2Cédric Rossi3Cédric Rossi4Cédric Rossi5Cédric Rossi6Pauline Gravelle7Pauline Gravelle8Pauline Gravelle9Pauline Gravelle10Camille Laurent11Camille Laurent12Camille Laurent13Camille Laurent14Julie Bordenave15Julie Bordenave16Julie Bordenave17Marie Tosolini18Anne Tourette19Emeline Perrial20Charles Dumontet21Mary Poupot22Mary Poupot23Mary Poupot24Christian Klein25Ariel Savina26Jean-Jacques Fournié27Jean-Jacques Fournié28Jean-Jacques Fournié29Christine Bezombes30Christine Bezombes31Christine Bezombes32Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceCHU Dijon, Hématologie Clinique, Hôpital François Mitterand, Dijon, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceDepartment of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceDepartment of Pathology, Institut Universitaire du Cancer de Toulouse, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FrancePôle Technologique du Centre de Recherches en Cancérologie de Toulouse, Toulouse, FranceINSERM1052/CNRS5286/Université Claude Bernard, Lyon, FranceINSERM1052/CNRS5286/Université Claude Bernard, Lyon, FranceINSERM1052/CNRS5286/Université Claude Bernard, Lyon, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandInstitut Roche, Boulogne-Billancourt, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceCentre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, Toulouse, FranceLaboratoire d'Excellence TOUCAN, Toulouse, FranceProgramme Hospitalo-Universitaire en Cancérologie CAPTOR, Toulouse, FranceFollicular lymphoma (FL) is the second most frequent subtype of B non-Hodgkin's lymphomas (NHL) for which the treatment is based on the use of anti-CD20 mAbs. NK cells play a crucial role in their mechanism of action and the number of these cells mediating antibody-dependent cell cycotoxicity (ADCC) in the peripheral blood of FL patients predict the outcome. However, their presence in FL biopsies, their activation and their role have been poorly investigated. Moreover, in vitro studies have not deciphered the exact signaling cascades triggered by NK cells in presence of anti-CD20 mAbs on both effector and target cells in a relevant FL model. We performed in silico analyses and ex vivo functional assays to determine the presence and the activation status of NK cells in FL biopsies. We modelized ADCC phenomenon by developing a co-culture model composed by 3D-cultured FL cells and NK cells. Thus, we investigated the biological effect of anti-CD20 mAbs by fluorescent microscopy and the phosphorylation status of survival pathways by cell bar coding phosphoflow in target cells. In parallel, we measured the status of activation of downstream FcγRIIIa signaling pathways in effector cells and their activation (CD69, perforin, granzyme B, IFNγ) by flow cytometry. We determined by in vivo experiments the effects of anti-CD20 mAbs in presence of NK cells in SCID-Beige engrafted FL mice. Here, we show that functional NK cells infiltrate FL biopsies, and that their presence tends to correlate with the survival of FL patients. Using our 3D co-culture model, we show that rituximab and GA101 are able to promote degranulation, CD69 expression, IFNγ production and activate FcγRIIIa signaling cascade in NK cells, and inhibit survival pathways and induce apoptosis in FL cells. The effect of GA101 seems to be more pronounced as observed in vivo in a xenograft FL model. This study strongly supports the role of NK cells in FL and highlights the application of the 3D co-culture model for in vitro validation.https://www.frontiersin.org/article/10.3389/fimmu.2019.01943/fullADCC—antibody dependent cellular cytotoxicityNK cellsmodelization3D co-culture modelfollicular lymphoma |